Opthea Revenue and Competitors
Employee Data
- Opthea has 58 Employees.
- Opthea grew their employee count by 61% last year.
Opthea's People
| Name | Title | Email/Phone |
|---|
Opthea Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $95.5M | 616 | -23% | N/A | N/A |
#2 | $34.7M | 224 | N/A | N/A | N/A |
#3 | $14.7M | 95 | -5% | N/A | N/A |
#4 | $15.8M | 102 | 6% | N/A | N/A |
#5 | $16.9M | 109 | 7% | N/A | N/A |
#6 | $22.5M | 145 | 4% | N/A | N/A |
#7 | $19.5M | 126 | -4% | N/A | N/A |
#8 | $10.4M | 67 | -29% | N/A | N/A |
#9 | $9.7M | 84 | -14% | $412.3M | N/A |
#10 | $24.2M | 156 | 2% | N/A | N/A |
What Is Opthea?
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age‐related macular degeneration (wet AMD) and diabetic macular edema (DME), which remain leading causes of vision loss worldwide. \n\nOpthea’s lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D ‘trap’ inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. Sozinibercept has the potential to become the first therapy in 20 years to enable patients with wet AMD to live fuller and healthier lives.
keywords:N/A
N/A
Total Funding
58
Number of Employees
N/A
Revenue (est)
61%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in South Yarra
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 58 | 21% | N/A |
#2 | $8M | 59 | 9% | N/A |
#3 | $13.3M | 59 | 13% | N/A |
#4 | $11.1M | 60 | 9% | N/A |
#5 | $15.8M | 65 | 7% | N/A |